CRIS Current Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishIn this study the raising and development of the antibody response to Borrelia burgdorferi infection in 66 Italian patients suffering from culture-confirmed Lyme borreliosis erythema migrans (EM) was investigated. 62/66 cultures obtained from the biopsies were identified as B. afzelii by PCR A total of 175 serially collected serum samples were tested by using two different sets of commercial assays: Enzygnost® Lyme link VlsE/IgG and Enzygnost® Borreliosis IgM (DADE Behring, Marburg, Germany) and LIAISON® Borrelia IgG and IgM (Saluggia Italy). Considering only samples obtained at first presentation when EM was clinically evident, 49/66 patients (72.4%) were IgG or IgM positive by Enzygnost®, whereas 33/66 (50.0%) patients were IgG or IgM positive by LIAISON®. Taking into account the follow up period, 8 patients sero-converted for IgG or IgM by Enzygnost® and 4 by LIAISON®. Similar and very good specificity values were obtained by all the methods, by testing sera obtained from blood donors (n=300) and from patients suffering from some of the most common biological conditions possibly resulting in false-positive reactivity in Lyme disease serology (n=100): Enzygnost® Lyme link VlsE/IgG was the more specific (98.3%), followed by LIAISON® Borrelia IgG (96.5%); considering IgM tests, Enzygnost® Borreliosis IgM showed to be 95.3%% specific, whereas the LIAISON® Borrelia IgM was 92.8% specific. Recombinant VlsE antigens obtained from all the three B.burgdorferi genospecies pathogenic to humans, included in Enzygnost® Lyme link VlsE/IgG, greatly improved serodiagnosis of Lyme disease.
| Titolo: | Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis. | |
| Autore/i: | MARANGONI, ANTONELLA; Moroni A.; ACCARDO, SILVIA; CEVENINI, ROBERTO | |
| Autore/i Unibo: | ||
| Anno: | 2008 | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/s10096-007-0445-7 | |
| Abstract: | In this study the raising and development of the antibody response to Borrelia burgdorferi infection in 66 Italian patients suffering from culture-confirmed Lyme borreliosis erythema migrans (EM) was investigated. 62/66 cultures obtained from the biopsies were identified as B. afzelii by PCR A total of 175 serially collected serum samples were tested by using two different sets of commercial assays: Enzygnost® Lyme link VlsE/IgG and Enzygnost® Borreliosis IgM (DADE Behring, Marburg, Germany) and LIAISON® Borrelia IgG and IgM (Saluggia Italy). Considering only samples obtained at first presentation when EM was clinically evident, 49/66 patients (72.4%) were IgG or IgM positive by Enzygnost®, whereas 33/66 (50.0%) patients were IgG or IgM positive by LIAISON®. Taking into account the follow up period, 8 patients sero-converted for IgG or IgM by Enzygnost® and 4 by LIAISON®. Similar and very good specificity values were obtained by all the methods, by testing sera obtained from blood donors (n=300) and from patients suffering from some of the most common biological conditions possibly resulting in false-positive reactivity in Lyme disease serology (n=100): Enzygnost® Lyme link VlsE/IgG was the more specific (98.3%), followed by LIAISON® Borrelia IgG (96.5%); considering IgM tests, Enzygnost® Borreliosis IgM showed to be 95.3%% specific, whereas the LIAISON® Borrelia IgM was 92.8% specific. Recombinant VlsE antigens obtained from all the three B.burgdorferi genospecies pathogenic to humans, included in Enzygnost® Lyme link VlsE/IgG, greatly improved serodiagnosis of Lyme disease. | |
| Data prodotto definitivo in UGOV: | 2011-01-24 16:03:38 | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
Copyright © 2022